Inxight Drugs

U.S. Department of Health & Human Services Divider Arrow

National Institutes of Health Divider Arrow

NCATS

Return Home Inxight Drugs

Home
Browse Drugs
Search
- Structure Search
- Sequence Search
Downloads
About

Show Filters

Hide Filters

Condition

Cold sores

11

Unknown

2,578

Pain

614

Cancer

592

Hypertension

567

All Match

Any Match

Exclude Selected

Exclude Selected

Development Status

US Approved Rx

8

US Previously Marketed

3

All Match

Any Match

Exclude Selected

Exclude Selected

Primary Target

Human herpesvirus 1 DNA polymerase

8

Thymidine kinase

8

All Match

Any Match

Exclude Selected

Exclude Selected

Highest Phase

Approved

11

All Match

Any Match

Exclude Selected

Exclude Selected

Approval Year

1982

8

1983

3

All Match

Any Match

Exclude Selected

Exclude Selected

Treatment Modality

Primary

11

Curative

3

Inactive ingredient

3

All Match

Any Match

Exclude Selected

Exclude Selected

CNS Activity

CNS Penetrant

8

All Match

Any Match

Exclude Selected

Exclude Selected

Originator

Burroughs Wellcome Fund

8

All Match

Any Match

Exclude Selected

Exclude Selected

Substance Class

Chemical

11

All Match

Any Match

Exclude Selected

Exclude Selected

Code System

CAS

11

FDA UNII

11

PUBCHEM

11

EPA CompTox

9

EVMPD

8

All Match

Any Match

Exclude Selected

Exclude Selected

ATC Level 1

ANTIINFECTIVES FOR SYSTEMIC USE

2

DERMATOLOGICALS

1

SENSORY ORGANS

1

All Match

Any Match

Exclude Selected

Exclude Selected

ATC Level 2

ANTIVIRALS FOR SYSTEMIC USE

2

ANTIBIOTICS AND CHEMOTHERAPEUTICS FOR DERMATOLOGICAL USE

1

OPHTHALMOLOGICALS

1

All Match

Any Match

Exclude Selected

Exclude Selected

ATC Level 3

DIRECT ACTING ANTIVIRALS

2

ANTIINFECTIVES

1

CHEMOTHERAPEUTICS FOR TOPICAL USE

1

All Match

Any Match

Exclude Selected

Exclude Selected

ATC Level 4

Nucleosides and nucleotides excl. reverse transcriptase inhibitors

2

Antivirals

1

All Match

Any Match

Exclude Selected

Exclude Selected

Substance Form

Salts, Hydrates, Esters, etc.

9

Principal Form

2

All Match

Any Match

Exclude Selected

Exclude Selected

Showing 1 - 10 of 11 results

First page disabled
Previous page disabled
1
Next page
Next page

ACYCLOVIR

X4HES1O11F

Export Data
Search for Structure

Status:

US Approved Rx (2019)

First approved in 1982

Class (Stereo):

CHEMICAL (ACHIRAL)

Targets:

Thymidine kinase

Human herpesvirus 1 DNA polymerase

Conditions:

Herpes zoster infections

Herpes simplex infection

Herpes zoster infections

Acyclovir is a synthetic antiviral nucleoside analogue. A screening program for antiviral drugs begun at Burroughs Wellcome in the 1960s resulted in the discovery of acyclovir in 1974. Preclinical investigation brought the drug to clinical trials in ...

1977 and the first form of the drug (topical) was available to physicians in 1982. Activity of acyclovir is greatest against herpes 1 and herpes 2, less against varicella zoster, still less against Epstein-Barr, and very little against cytomegalovirus. Acyclovir is an antiviral agent only after it is phosphorylated in infected cells by a viral-induced thymidine kinase. Acyclovir monophosphate is phosphorylated to diphosphate and triphosphate forms by cellular enzymes in the infected host cell where the drug is concentrated. Acyclovir triphosphate inactivates viral deoxyribonucleic acid polymerase.

CETALKONIUM

FHG725432Z

Export Data
Search for Structure

Status:

US Previously Marketed

First approved in 1983

Class (Stereo):

CHEMICAL (ACHIRAL)

Conditions:

Dry eye syndrome

Cetalkonium chloride is a cationic quaternary ammonium surfactant, which is used for the treatment of mouth ulcers and sores (Bonjela trade name). It is also serves as an excipient for the purpose of long-term stabilization of ciclosporin ocular form...

ulation, used in patients with dry eye syndrom (Ikervis trade name). The antibacterial properties of cetalkonium can be explained by its detergent character. Once applied, cetalkonium blocks the survival of biofilm forming bacterias.

Acyclovir Sodium Dihydrate

TZT3J8XU9F

Export Data
Search for Structure

Status:

US Approved Rx (2019)

First approved in 1982

Class (Stereo):

CHEMICAL (ACHIRAL)

Targets:

Thymidine kinase

Human herpesvirus 1 DNA polymerase

Conditions:

Herpes zoster infections

Herpes simplex infection

Herpes zoster infections

Acyclovir is a synthetic antiviral nucleoside analogue. A screening program for antiviral drugs begun at Burroughs Wellcome in the 1960s resulted in the discovery of acyclovir in 1974. Preclinical investigation brought the drug to clinical trials in ...

1977 and the first form of the drug (topical) was available to physicians in 1982. Activity of acyclovir is greatest against herpes 1 and herpes 2, less against varicella zoster, still less against Epstein-Barr, and very little against cytomegalovirus. Acyclovir is an antiviral agent only after it is phosphorylated in infected cells by a viral-induced thymidine kinase. Acyclovir monophosphate is phosphorylated to diphosphate and triphosphate forms by cellular enzymes in the infected host cell where the drug is concentrated. Acyclovir triphosphate inactivates viral deoxyribonucleic acid polymerase.

VALACYCLOVIR

MZ1IW7Q79D

Export Data
Search for Structure

Status:

US Approved Rx (2019)

First approved in 1982

Class (Stereo):

CHEMICAL (ABSOLUTE)

Targets:

Thymidine kinase

Human herpesvirus 1 DNA polymerase

Conditions:

Herpes zoster infections

Herpes simplex infection

Herpes zoster infections

Acyclovir is a synthetic antiviral nucleoside analogue. A screening program for antiviral drugs begun at Burroughs Wellcome in the 1960s resulted in the discovery of acyclovir in 1974. Preclinical investigation brought the drug to clinical trials in ...

1977 and the first form of the drug (topical) was available to physicians in 1982. Activity of acyclovir is greatest against herpes 1 and herpes 2, less against varicella zoster, still less against Epstein-Barr, and very little against cytomegalovirus. Acyclovir is an antiviral agent only after it is phosphorylated in infected cells by a viral-induced thymidine kinase. Acyclovir monophosphate is phosphorylated to diphosphate and triphosphate forms by cellular enzymes in the infected host cell where the drug is concentrated. Acyclovir triphosphate inactivates viral deoxyribonucleic acid polymerase.

VALACYCLOVIR HYDROCHLORIDE MONOHYDRATE

JF64RVR4E3

Export Data
Search for Structure

Status:

US Approved Rx (2019)

First approved in 1982

Class (Stereo):

CHEMICAL (ABSOLUTE)

Targets:

Thymidine kinase

Human herpesvirus 1 DNA polymerase

Conditions:

Herpes zoster infections

Herpes simplex infection

Herpes zoster infections

Acyclovir is a synthetic antiviral nucleoside analogue. A screening program for antiviral drugs begun at Burroughs Wellcome in the 1960s resulted in the discovery of acyclovir in 1974. Preclinical investigation brought the drug to clinical trials in ...

1977 and the first form of the drug (topical) was available to physicians in 1982. Activity of acyclovir is greatest against herpes 1 and herpes 2, less against varicella zoster, still less against Epstein-Barr, and very little against cytomegalovirus. Acyclovir is an antiviral agent only after it is phosphorylated in infected cells by a viral-induced thymidine kinase. Acyclovir monophosphate is phosphorylated to diphosphate and triphosphate forms by cellular enzymes in the infected host cell where the drug is concentrated. Acyclovir triphosphate inactivates viral deoxyribonucleic acid polymerase.

ACYCLOVIR SODIUM

927L42J563

Export Data
Search for Structure

Status:

US Approved Rx (2019)

First approved in 1982

Class (Stereo):

CHEMICAL (ACHIRAL)

Targets:

Thymidine kinase

Human herpesvirus 1 DNA polymerase

Conditions:

Herpes zoster infections

Herpes simplex infection

Herpes zoster infections

Acyclovir is a synthetic antiviral nucleoside analogue. A screening program for antiviral drugs begun at Burroughs Wellcome in the 1960s resulted in the discovery of acyclovir in 1974. Preclinical investigation brought the drug to clinical trials in ...

1977 and the first form of the drug (topical) was available to physicians in 1982. Activity of acyclovir is greatest against herpes 1 and herpes 2, less against varicella zoster, still less against Epstein-Barr, and very little against cytomegalovirus. Acyclovir is an antiviral agent only after it is phosphorylated in infected cells by a viral-induced thymidine kinase. Acyclovir monophosphate is phosphorylated to diphosphate and triphosphate forms by cellular enzymes in the infected host cell where the drug is concentrated. Acyclovir triphosphate inactivates viral deoxyribonucleic acid polymerase.

VALACYCLOVIR HYDROCHLORIDE DIHYDRATE

A7JO128919

Export Data
Search for Structure

Status:

US Approved Rx (2019)

First approved in 1982

Class (Stereo):

CHEMICAL (ABSOLUTE)

Targets:

Thymidine kinase

Human herpesvirus 1 DNA polymerase

Conditions:

Herpes zoster infections

Herpes simplex infection

Herpes zoster infections

Acyclovir is a synthetic antiviral nucleoside analogue. A screening program for antiviral drugs begun at Burroughs Wellcome in the 1960s resulted in the discovery of acyclovir in 1974. Preclinical investigation brought the drug to clinical trials in ...

1977 and the first form of the drug (topical) was available to physicians in 1982. Activity of acyclovir is greatest against herpes 1 and herpes 2, less against varicella zoster, still less against Epstein-Barr, and very little against cytomegalovirus. Acyclovir is an antiviral agent only after it is phosphorylated in infected cells by a viral-induced thymidine kinase. Acyclovir monophosphate is phosphorylated to diphosphate and triphosphate forms by cellular enzymes in the infected host cell where the drug is concentrated. Acyclovir triphosphate inactivates viral deoxyribonucleic acid polymerase.

VALACYCLOVIR HYDROCHLORIDE

G447S0T1VC

Export Data
Search for Structure

Status:

US Approved Rx (2019)

First approved in 1982

Class (Stereo):

CHEMICAL (ABSOLUTE)

Targets:

Thymidine kinase

Human herpesvirus 1 DNA polymerase

Conditions:

Herpes zoster infections

Herpes simplex infection

Herpes zoster infections

Acyclovir is a synthetic antiviral nucleoside analogue. A screening program for antiviral drugs begun at Burroughs Wellcome in the 1960s resulted in the discovery of acyclovir in 1974. Preclinical investigation brought the drug to clinical trials in ...

1977 and the first form of the drug (topical) was available to physicians in 1982. Activity of acyclovir is greatest against herpes 1 and herpes 2, less against varicella zoster, still less against Epstein-Barr, and very little against cytomegalovirus. Acyclovir is an antiviral agent only after it is phosphorylated in infected cells by a viral-induced thymidine kinase. Acyclovir monophosphate is phosphorylated to diphosphate and triphosphate forms by cellular enzymes in the infected host cell where the drug is concentrated. Acyclovir triphosphate inactivates viral deoxyribonucleic acid polymerase.

DESCICLOVIR

BHM1XXA2EZ

Export Data
Search for Structure

Status:

US Approved Rx (2019)

First approved in 1982

Class (Stereo):

CHEMICAL (ACHIRAL)

Targets:

Thymidine kinase

Human herpesvirus 1 DNA polymerase

Conditions:

Herpes zoster infections

Herpes simplex infection

Herpes zoster infections

Acyclovir is a synthetic antiviral nucleoside analogue. A screening program for antiviral drugs begun at Burroughs Wellcome in the 1960s resulted in the discovery of acyclovir in 1974. Preclinical investigation brought the drug to clinical trials in ...

1977 and the first form of the drug (topical) was available to physicians in 1982. Activity of acyclovir is greatest against herpes 1 and herpes 2, less against varicella zoster, still less against Epstein-Barr, and very little against cytomegalovirus. Acyclovir is an antiviral agent only after it is phosphorylated in infected cells by a viral-induced thymidine kinase. Acyclovir monophosphate is phosphorylated to diphosphate and triphosphate forms by cellular enzymes in the infected host cell where the drug is concentrated. Acyclovir triphosphate inactivates viral deoxyribonucleic acid polymerase.

CETALKONIUM CHLORIDE

85474O1N9D

Export Data
Search for Structure

Status:

US Previously Marketed

First approved in 1983

Class (Stereo):

CHEMICAL (ACHIRAL)

Conditions:

Dry eye syndrome

Cetalkonium chloride is a cationic quaternary ammonium surfactant, which is used for the treatment of mouth ulcers and sores (Bonjela trade name). It is also serves as an excipient for the purpose of long-term stabilization of ciclosporin ocular form...

ulation, used in patients with dry eye syndrom (Ikervis trade name). The antibacterial properties of cetalkonium can be explained by its detergent character. Once applied, cetalkonium blocks the survival of biofilm forming bacterias.

Showing 1 - 10 of 11 results

First page disabled
Previous page disabled
1
Next page
Next page

HHS VULNERABILITY DISCLOSURE

For language access assistance, contact the NCATS Public Information Officer

National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966


			version 1.1